Earnings call transcript: Honeywell Q1 2026 beats EPS expectations, stock dips

Honeywell posted Q1 2026 EPS of $2.45, ahead of the $2.32 consensus by 5.6%, but revenue missed at $9.14B versus $9.28B expected and shares fell 5.02% pre-market to $208.92. Management kept FY2026 guidance unchanged, citing strong backlog and demand in Building Automation and Aerospace, but flagged ongoing Middle East conflict and aerospace supply-chain disruptions as near-term headwinds. The company also advanced its portfolio reshaping with the Aerospace spin-off still targeted for June 29 and continued capital returns of $1.8B in the quarter.

Analysis

The market is treating HON like a quality cyclically levered industrial with no near-term catalyst, but the setup is more nuanced: the miss is in revenue quality, not demand breadth. Margin outperformance plus backlog acceleration suggests the top-line gap is mostly timing and logistics, which means the earnings revision cycle is likely more shallow than the pre-market tape implies. The real issue is that investors are paying a premium multiple for a company in the middle of a portfolio reset, so any transient shipment disruption gets amplified by de-rating risk.

Second-order, the Middle East disruption is hurting the highest-margin parts of the mix first, so the earnings impact is larger than the revenue impact alone would suggest. That creates a rebound asymmetry: if logistics normalize over the next 1-2 quarters, the same revenue can re-enter at materially better margins because service/software and catalyst conversion should recover faster than pure equipment sales. The backlog commentary also matters for competitors — this is not a weak end-market signal, it is a fulfillment bottleneck, which tends to transfer share only if the issue persists beyond a couple of quarters.

The more interesting trade is on the industrial complex rather than HON outright. HON’s reset to a purer automation asset could support a rerating over 6-12 months, but only after the spin/divestiture overhang clears and guidance credibility improves. Near term, the tape is vulnerable because the stock has less room to absorb any further negative headline on geopolitics, supply chain, or tax/mix in Q2; that makes this a better buy-on-weakness candidate than an immediate momentum long.

Consensus is probably underestimating how quickly margins can rebound once the mix normalizes. The flip side is that consensus may be overestimating how much of the backlog converts into same-quarter sales, which is why the next two prints matter more than the full-year guide. If the company proves Q2 sequential improvement and cleaner post-spin disclosure, the de-rating should reverse quickly; if not, the premium multiple is fragile.

Key Decisions for Investors

• Short HON into any relief rally over the next 1-2 weeks; target a 5-8% downside move if Q2 margin/mix concerns stay front and center, with a tight stop above the pre-market gap fill.
• Pair trade: long HON / short EMR or ROK on a 6-12 month horizon if you want to express a quality industrial rebound; HON has the cleaner backlog/margin inflection, while the peers have less embedded restructuring optionality.
• If owning HON, use downside puts into the next earnings cycle rather than outright long stock; the premium multiple plus geopolitical headline risk makes the skew attractive for a 2-3 month hedge.
• Watch for a buy-the-dip entry only after management confirms uninterrupted March-April aerospace recovery and clearer Middle East normalization; that is the trigger for a re-entry, not today’s print.
• Consider a relative long HON vs a basket of lower-quality automation names if the market starts rewarding backlog conversion over headline revenue growth; this is a 6-12 month rerating call, not a same-day trade.